HUP0203160A2 - Prevention of plaque rupture by acat inhibitors - Google Patents

Prevention of plaque rupture by acat inhibitors

Info

Publication number
HUP0203160A2
HUP0203160A2 HU0203160A HUP0203160A HUP0203160A2 HU P0203160 A2 HUP0203160 A2 HU P0203160A2 HU 0203160 A HU0203160 A HU 0203160A HU P0203160 A HUP0203160 A HU P0203160A HU P0203160 A2 HUP0203160 A2 HU P0203160A2
Authority
HU
Hungary
Prior art keywords
plaque rupture
acat inhibitors
prevention
acat
inhibiting
Prior art date
Application number
HU0203160A
Other languages
Hungarian (hu)
Inventor
Thomas Michael Andrew Bocan
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of HUP0203160A2 publication Critical patent/HUP0203160A2/en
Publication of HUP0203160A3 publication Critical patent/HUP0203160A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A találmány ateroszklerotikus léziókban monocita- makrofágfelhalmozódás gátlására, plakk ruptura kialakulásánakmegakadályozására, mátrix-metalloproteináz expressziójának gátlására,instabil angina kezelésére szolgáló eljárásokra vonatkozik emlősökben,különösen emberben, amely abban áll, hogy egy ACAT inhibitorterápiásan hatékony mennyiségét az ilyen kezelésre rászoruló emlősnekbeadják. A találmány szerinti eljárásokban ACAT inhibitorkéntelőnyösen helyettesített szulfominsavszármazékokat vagytetrazidszármazékokat alkalmaznak. ÓThe invention relates to methods for inhibiting monocyte-macrophage accumulation in atherosclerotic lesions, preventing plaque rupture, inhibiting matrix metalloproteinase expression, and treating unstable angina in mammals, especially in humans, which consists in administering a therapeutically effective amount of an ACAT inhibitor to the mammal in need of such treatment. In the methods according to the invention, substituted sulfominic acid derivatives or tetrazide derivatives are preferably used as ACAT inhibitors. HE

HU0203160A 1999-11-05 2000-10-17 Prevention of plaque rupture by acat inhibitors HUP0203160A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16381499P 1999-11-05 1999-11-05
PCT/US2000/028705 WO2001034127A1 (en) 1999-11-05 2000-10-17 Prevention of plaque rupture by acat inhibitors

Publications (2)

Publication Number Publication Date
HUP0203160A2 true HUP0203160A2 (en) 2003-01-28
HUP0203160A3 HUP0203160A3 (en) 2006-02-28

Family

ID=22591694

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203160A HUP0203160A3 (en) 1999-11-05 2000-10-17 Prevention of plaque rupture by acat inhibitors

Country Status (19)

Country Link
EP (1) EP1229907A1 (en)
JP (1) JP2003513909A (en)
KR (1) KR20020050257A (en)
CN (1) CN1414848A (en)
AR (1) AR026354A1 (en)
AU (1) AU1210401A (en)
CA (1) CA2382676A1 (en)
CO (1) CO5270017A1 (en)
GT (1) GT200000193A (en)
HU (1) HUP0203160A3 (en)
IL (1) IL149145A0 (en)
PA (1) PA8506101A1 (en)
PE (1) PE20011027A1 (en)
PL (1) PL355148A1 (en)
SV (1) SV2001000207A (en)
TR (1) TR200201204T2 (en)
UY (1) UY26427A1 (en)
WO (1) WO2001034127A1 (en)
ZA (1) ZA200201755B (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060111898A (en) 2003-08-29 2006-10-30 교와 가부시키가이샤 Method of stabilizing lipid-rich plaque and method of preventing rupture thereof
US20080044404A1 (en) * 2004-04-15 2008-02-21 Anna Cederholm Annexin V for Preventing Atherothrombosis and Plaque Rupture
ES2775125T3 (en) 2010-11-03 2020-07-23 Dow Agrosciences Llc Pesticide compositions and related procedures
US8937083B2 (en) 2011-10-26 2015-01-20 DowAgroSciences, LLC Pesticidal compositions and processes related thereto
US9282739B2 (en) 2012-04-27 2016-03-15 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
JP6189937B2 (en) 2012-04-27 2017-08-30 ダウ アグロサイエンシィズ エルエルシー Agrochemical compositions and methods relating thereto
US9708288B2 (en) 2012-04-27 2017-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
JP2016536296A (en) 2013-10-17 2016-11-24 ダウ アグロサイエンシィズ エルエルシー Method for producing pest control compound
JP2016536295A (en) 2013-10-17 2016-11-24 ダウ アグロサイエンシィズ エルエルシー Method for producing pest control compound
CN105636446B (en) 2013-10-17 2018-07-13 美国陶氏益农公司 The method for preparing Pesticidal compound
KR20160072155A (en) 2013-10-17 2016-06-22 다우 아그로사이언시즈 엘엘씨 Processes for the preparation of pesticidal compounds
JP2016535010A (en) 2013-10-17 2016-11-10 ダウ アグロサイエンシィズ エルエルシー Method for producing pest control compound
US9102655B2 (en) 2013-10-17 2015-08-11 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
KR20160072154A (en) 2013-10-17 2016-06-22 다우 아그로사이언시즈 엘엘씨 Processes for the preparation of pesticidal compounds
EP3060052A4 (en) 2013-10-22 2017-04-05 Dow AgroSciences LLC Synergistic pesticidal compositions and related methods
AR098098A1 (en) 2013-10-22 2016-05-04 Dow Agrosciences Llc SYNERGIC PESTICIATED COMPOSITIONS AND RELATED METHODS
CN105828610B (en) 2013-10-22 2019-07-19 美国陶氏益农公司 Pesticidal combination and relative method
JP2016534086A (en) 2013-10-22 2016-11-04 ダウ アグロサイエンシィズ エルエルシー Synergistic pest control compositions and related methods
MX2016005316A (en) 2013-10-22 2017-03-01 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods.
CA2926438A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Pesticidal compositions and related methods
MX2016005323A (en) 2013-10-22 2016-08-12 Dow Agrosciences Llc Pesticidal compositions and related methods.
JP2016535025A (en) 2013-10-22 2016-11-10 ダウ アグロサイエンシィズ エルエルシー Synergistic pest control compositions and related methods
WO2015061155A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Pesticidal compositions and related methods
KR20160074621A (en) 2013-10-22 2016-06-28 다우 아그로사이언시즈 엘엘씨 Synergistic pesticidal compositions and related methods
CN105848480A (en) 2013-10-22 2016-08-10 美国陶氏益农公司 Synergistic pesticidal compositions and related methods
TW201519780A (en) 2013-10-22 2015-06-01 Dow Agrosciences Llc Pesticidal compositions and related methods
MX2016005325A (en) 2013-10-22 2016-08-08 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods.
EP3060055A4 (en) 2013-10-22 2017-03-29 Dow AgroSciences LLC Synergistic pesticidal compositions and related methods
US9808008B2 (en) 2013-10-22 2017-11-07 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
CA2927202A1 (en) 2013-10-22 2015-04-30 Dow Agrosciences Llc Synergistic pesticidal compositions and related methods
AU2014340430B2 (en) 2013-10-22 2017-05-25 Dow Agrosciences Llc Pesticidal compositions and related methods
CN106470976A (en) 2014-07-31 2017-03-01 美国陶氏益农公司 The method of preparation 3 (3 chlorine 1H pyrazoles 1 base) pyridine
EP3186229A4 (en) 2014-07-31 2018-01-10 Dow AgroSciences LLC Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
EP3174856A4 (en) 2014-07-31 2018-01-10 Dow AgroSciences LLC Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
US9024031B1 (en) 2014-08-19 2015-05-05 Dow Agrosciences Llc Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
BR112017004613A2 (en) 2014-09-12 2017-12-05 Dow Agrosciences Llc Process for the preparation of 3- (3-chloro-1h-pyrazol-1-yl) pyridine
CA2961166C (en) * 2014-10-21 2021-04-13 Council Of Scientific And Industrial Research Alkylidene phosphonate esters as p-glycoprotein inducers
US20190275012A9 (en) * 2016-07-29 2019-09-12 Lupin Limited Substituted thiazolo-pyridine compounds as malt1 inhibitors
WO2018093966A1 (en) * 2016-11-16 2018-05-24 Purdue Research Foundation Compositions and methods for regulating body weight and metabolic syndromes
WO2018125817A1 (en) 2016-12-29 2018-07-05 Dow Agrosciences Llc Processes for the preparation of pesticidal compounds
EP3562807B1 (en) 2016-12-29 2022-08-03 Corteva Agriscience LLC Processes for the preparation of pesticidal compounds
CU20200038A7 (en) 2017-10-27 2021-03-11 Bayer Ag COMPOUNDS DERIVED FROM PYRAZOLO-PIRROLO-PYRIMIDINE-DIONA AS INHIBITORS OF P2X3
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2067254T3 (en) * 1990-10-30 1995-03-16 Warner Lambert Co OXISULFONILCARBAMATOS.
IL109431A (en) * 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
IT1270976B (en) * 1993-08-06 1997-05-26 Pierrel Spa INHIBITIVE COMPOUNDS OF ACYL ENZYME-A-CHOLESTEROL-O-ACYL TRANSFERASE TO THERAPEUTIC ACTIVITIES, THEIR USE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
EE9800037A (en) * 1995-08-04 1998-08-17 Warner-Lambert Company Use of sulphamic acid derivatives, acylsulphonamides or sulphonylcarbamates in the manufacture of a medicament for reducing lipoprotein levels
WO1997016184A1 (en) * 1995-11-02 1997-05-09 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration
OA11584A (en) * 1998-07-21 2004-07-20 Warner Lambert Co Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions.

Also Published As

Publication number Publication date
WO2001034127A1 (en) 2001-05-17
CN1414848A (en) 2003-04-30
TR200201204T2 (en) 2002-08-21
PE20011027A1 (en) 2001-10-16
CO5270017A1 (en) 2003-04-30
PL355148A1 (en) 2004-04-05
GT200000193A (en) 2002-04-27
AU1210401A (en) 2001-06-06
CA2382676A1 (en) 2001-05-17
PA8506101A1 (en) 2002-10-28
JP2003513909A (en) 2003-04-15
UY26427A1 (en) 2000-12-29
ZA200201755B (en) 2003-08-27
SV2001000207A (en) 2001-10-16
HUP0203160A3 (en) 2006-02-28
AR026354A1 (en) 2003-02-05
IL149145A0 (en) 2002-11-10
EP1229907A1 (en) 2002-08-14
KR20020050257A (en) 2002-06-26

Similar Documents

Publication Publication Date Title
HUP0203160A2 (en) Prevention of plaque rupture by acat inhibitors
HUP9900655A1 (en) Method of inhibiting photoaging of skin
DK1257550T3 (en) The platelet ADP receptor inhibitor
HUP9902103A2 (en) Triaryl compounds
PT971713E (en) USE OF COLINESTERASE INHIBITORS FOR TREATMENT OF ATENTION DISORDERS
NO20003018D0 (en) Triazinangiogenese inhibitors
ATE181334T1 (en) INHIBITORS AGAINST THROMBOSIS
HUP0100156A2 (en) Indole derivatives as inhibitors of phospholipase a2 and use of them for producing pharmaceutical compositions
DE69816280D1 (en) INHIBITORS OF THE IMPDH ENZYME
GT200100005A (en) TREATMENT OF NEURODEGENERATIVE DISEASE
TR200200515T2 (en) The use of renin-angiotensin system inhibitors in the prevention of cardiovascular cases.
CY1112932T1 (en) Suspensions SMAD7 FOR CNS DISEASE TREATMENT
BR0316583A (en) Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (parent-1)
EA200100804A1 (en) SULPHOOROMATIC DERIVATIVES OF HYDROXAMIC ACID AS METHYPE PROTEASIS INHIBITORS
WO2000061167A3 (en) TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
IS5985A (en) Cells-suppressing inflammatory-destroying and immunosuppressive compounds
DK0946166T3 (en) Use of matrix metalloproteinase inhibitors to promote wound healing
CY1119190T1 (en) Use of IL-18 inhibitors to treat or prevent CNS lesions
FI951298A0 (en) 2-Amino-4-phenyl-4-oxobutyric acid derivatives having kynureninase and / or kynurenine-3-hydroxylase inhibitory activity
EA200401183A1 (en) APPLICATION OF IL-18 INHIBITORS AS A DIAGNOSTIC MARKER
TR199801705T2 (en) Serine protease inhibitors.
EP0930067A3 (en) MMP inhibitors for the treatment of ocular angiogenesis
DK1032556T3 (en) Pharmaceutically active compounds and methods of use
ATE245623T1 (en) COMPOUNDS WITH CYTOPROTECTION ACTION
BR9910678A (en) Compound, pharmaceutical composition, method for treating or preventing an inflammatory disease, method for treating a condition or disease mediated by mmps, tnf, agrecanase, or a compound thereof, in a mammal, method of reducing tnf levels in patients, without mmps inhibition, method for treating a condition or disease and using a new compound

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees